

## PDE1-IN-7

## Chemical Properties


CAS No. : 3027833-49-1

Formula: C<sub>32</sub>H<sub>36</sub>F<sub>2</sub>N<sub>2</sub>O<sub>6</sub>S

Molecular Weight: 614.7

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	PDE1-IN-7 (Compound 13h), with an IC <sub>50</sub> value of 10 nM, selectively inhibits bPDE1. This compound demonstrates significant anti-fibrotic effects in a BDL-induced liver fibrosis rat model and is useful for research purposes in studying liver fibrosis [1].
Targets(IC <sub>50</sub> )	PDE
In vitro	PDE1-IN-7 (concentration of 2.5-20 μM; incubation time of 48 hours) dose-dependently reduces the expression levels of fibronectin, collagen I, and α-SMA induced by TGF-β in human hepatic stellate cells LX-2, effectively inhibiting the myofibroblast differentiation and proliferation triggered by TGF-β in these cells [1]. The effects of PDE1-IN-7 on LX-2 cells were confirmed via Western Blot Analysis [1], validating its impact.
In vivo	Administered intraperitoneally (i.p.) at a dose of 2.5 mg/kg daily for 21 days, PDE1-IN-7 demonstrated significant antifibrotic effects in a rat model of bile duct ligation (BDL)-induced liver fibrosis [1]. Pharmacokinetic analysis following an intravenous (i.v.) injection of 2.5 mg/kg revealed a half-life of 7.51 ± 0.64 hours, a maximum concentration (C <sub>max</sub> ) of 25,006 ± 3082 ng/mL, an area under the curve (AUC <sub>∞</sub> ) of 6317 ± 839 (h)(ng·/mL), a clearance rate (Cl <sub>obs</sub> ) of 6.56 ± 0.81 mL/min/kg, a mean residence time (MRT) of 1.77 ± 0.07 hours, and a steady-state volume of distribution (V <sub>ss_obs</sub> ) of 698 ± 104 mL/kg. The compound significantly reduced levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bile acids (TBA), alleviated structural damage in liver tissues, decreased fibrotic lesions and collagen deposition, and markedly reduced the protein expression levels of α-SMA and collagen I, while notably increasing cAMP levels.

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	1.6268 mL	8.134 mL	16.2681 mL
5 mM	0.3254 mL	1.6268 mL	3.2536 mL
10 mM	0.1627 mL	0.8134 mL	1.6268 mL
50 mM	0.0325 mL	0.1627 mL	0.3254 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481